Overview

Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether DCVAC/PCa added onto Standard of Care Chemotherapy can improve survival times for patients with Metastatic Castration Resistant Prostate Cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Sotio a.s.
Treatments:
Docetaxel
Prednisone